Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP893564.RAaLbsd9b0zqZvDWLsaNLe8I8ytNZJZ0wQoqvkT19R2j0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP893564.RAaLbsd9b0zqZvDWLsaNLe8I8ytNZJZ0wQoqvkT19R2j0130_assertion type Assertion NP893564.RAaLbsd9b0zqZvDWLsaNLe8I8ytNZJZ0wQoqvkT19R2j0130_head.
- NP893564.RAaLbsd9b0zqZvDWLsaNLe8I8ytNZJZ0wQoqvkT19R2j0130_assertion wasGeneratedBy ECO_0000203 NP893564.RAaLbsd9b0zqZvDWLsaNLe8I8ytNZJZ0wQoqvkT19R2j0130_provenance.
- NP893564.RAaLbsd9b0zqZvDWLsaNLe8I8ytNZJZ0wQoqvkT19R2j0130_assertion wasDerivedFrom befree-20140225 NP893564.RAaLbsd9b0zqZvDWLsaNLe8I8ytNZJZ0wQoqvkT19R2j0130_provenance.
- NP893564.RAaLbsd9b0zqZvDWLsaNLe8I8ytNZJZ0wQoqvkT19R2j0130_assertion SIO_000772 12955575 NP893564.RAaLbsd9b0zqZvDWLsaNLe8I8ytNZJZ0wQoqvkT19R2j0130_provenance.
- NP893564.RAaLbsd9b0zqZvDWLsaNLe8I8ytNZJZ0wQoqvkT19R2j0130_assertion evidence source_evidence_literature NP893564.RAaLbsd9b0zqZvDWLsaNLe8I8ytNZJZ0wQoqvkT19R2j0130_provenance.
- NP893564.RAaLbsd9b0zqZvDWLsaNLe8I8ytNZJZ0wQoqvkT19R2j0130_assertion description "[The large phase II study of Iressa (IDEAL1) in patients with non-small-cell lung cancer (NSCLC) in whom previous platinum-based therapy has failed, found that the median survival time (MST) was 7.6 months, which was no less than that with Docetaxel treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP893564.RAaLbsd9b0zqZvDWLsaNLe8I8ytNZJZ0wQoqvkT19R2j0130_provenance.